Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations.

Rogers A, Flynn RWV, Mackenzie IS, MacDonald TM.

BMC Med Res Methodol. 2019 Jan 30;19(1):24. doi: 10.1186/s12874-019-0663-6.

2.

The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD.

Flynn RWV, MacDonald TM, Chalmers JD, Schembri S.

Respir Res. 2018 Dec 12;19(1):249. doi: 10.1186/s12931-018-0960-3.

3.

Identifying poor adherence to antihypertensive medications in patients with resistant hypertension.

Mackenzie IS, MacDonald TM.

Br J Clin Pharmacol. 2019 Jan;85(1):5-7. doi: 10.1111/bcp.13806. Epub 2018 Nov 26. No abstract available.

4.

The effect of indapamide vs. bendroflumethiazide for primary hypertension: a systematic review.

Macfarlane TV, Pigazzani F, Flynn RWV, MacDonald TM.

Br J Clin Pharmacol. 2019 Feb;85(2):285-303. doi: 10.1111/bcp.13787. Epub 2018 Nov 28. Review.

PMID:
30312512
5.

Ibuprofen and Paracetamol: Acceptably Safe for All?

Pigazzani F, Mackenzie I, MacDonald TM.

Drug Saf. 2018 Nov;41(11):999-1001. doi: 10.1007/s40264-018-0717-4. No abstract available.

6.
7.

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11. Erratum in: Lancet Diabetes Endocrinol. 2018 Aug;6(8):e16.

8.

The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment.

Rorie DA, Flynn RWV, Mackenzie IS, MacDonald TM, Rogers A.

Trials. 2017 Nov 23;18(1):557. doi: 10.1186/s13063-017-2318-4.

9.

Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.

MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Brown MJ; British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm‐based Therapy (PATHWAY).

J Am Heart Assoc. 2017 Nov 18;6(11). pii: e006986. doi: 10.1161/JAHA.117.006986.

10.

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.

Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, Doney ASF.

Clin Pharmacol Ther. 2018 Feb;103(2):281-286. doi: 10.1002/cpt.780. Epub 2017 Sep 19.

11.

Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology.

Rorie DA, Flynn RWV, Grieve K, Doney A, Mackenzie I, MacDonald TM, Rogers A.

Br J Clin Pharmacol. 2017 Sep;83(9):1880-1895. doi: 10.1111/bcp.13285. Epub 2017 Apr 22. Review.

12.

Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.

Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM.

Br J Clin Pharmacol. 2017 Jun;83(6):1298-1308. doi: 10.1111/bcp.13205. Epub 2017 Jan 23.

13.

Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.

Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM.

Br J Clin Pharmacol. 2017 Mar;83(3):653-663. doi: 10.1111/bcp.13152. Epub 2016 Nov 12.

14.

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).

MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A, Wei L, Mackenzie IS.

Eur Heart J. 2017 Jun 14;38(23):1843-1850. doi: 10.1093/eurheartj/ehw387. Erratum in: Eur Heart J. 2016 Dec 24;:.

15.

Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.

Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, Taggar J, Wei L, Struthers AD, MacDonald TM; ALL-HEART study group.

BMJ Open. 2016 Sep 8;6(9):e013774. doi: 10.1136/bmjopen-2016-013774.

17.

PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.

Williams B, MacDonald TM, Morant SV, Brown MJ.

Lancet. 2016 Apr 2;387(10026):1373-1374. doi: 10.1016/S0140-6736(16)00698-X. No abstract available.

PMID:
27115814
18.

Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study.

Rorie DA, Rogers A, Mackenzie IS, Ford I, Webb DJ, Willams B, Brown M, Poulter N, Findlay E, Saywood W, MacDonald TM.

BMJ Open. 2016 Feb 9;6(2):e010313. doi: 10.1136/bmjopen-2015-010313.

19.

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.

Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group.

Lancet Diabetes Endocrinol. 2016 Feb;4(2):136-47. doi: 10.1016/S2213-8587(15)00377-0. Epub 2015 Oct 18.

20.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group.

Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.

Supplemental Content

Loading ...
Support Center